Audited annual filings, TTM ratios and consensus forward estimates
Wall Street price targets and rating actions
Revenue disaggregation per 10-K filing
Annual filings (FY) with consensus forward estimates (hatched)
1255 daily bars · split adjusted
Current price $6.33
Latest analyst grade actions
| Date | Firm | Action | Previous | New grade |
|---|---|---|---|---|
| Oct 22, 26 |
Daily · Wilder smoothing
| Chardan Capital |
| maintain |
| Buy |
| Buy |
| Oct 5, 26 | Chardan Capital | maintain | Buy | Buy |
| Aug 11, 26 | HC Wainwright & Co. | maintain | Buy | Buy |
| Jul 30, 26 | B. Riley Securities | maintain | Buy | Buy |
| Jul 13, 26 | HC Wainwright & Co. | maintain | Buy | Buy |
| Sep 10, 25 | HC Wainwright & Co. | maintain | Buy | Buy |
| Aug 28, 25 | HC Wainwright & Co. | maintain | Buy | Buy |
| Jun 4, 25 | HC Wainwright & Co. | upgrade | Neutral | Buy |
| Jun 4, 25 | H.C. Wainwright | upgrade | Neutral | Buy |
Classic floor pivots from 2026-10-23
Computed from daily OHLCV bars
| Indicator | Value | Type | Action |
|---|---|---|---|
| RSI (14) | 38.58 | Oscillator | Neutral |
| Stochastic %K (14, 3, 3) | 15.41 | Oscillator | Buy |
| Williams %R (14) | -86.75 | Oscillator | Buy |
| MACD (12, 26, 9) | -0.44 (Hist -0.14) | Oscillator | Strong Sell |
| Average Directional Index (14) | 22.72 (+DI 17.2 / -DI 27.9) | Trend | Sell |
| EMA 20 | 7.08 | MA | Strong Sell |
| SMA 20 | 7.52 | MA | Strong Sell |
| EMA 50 | 7.19 | MA | Strong Sell |
| SMA 50 | 7.67 | MA | Strong Sell |
| SMA 200 | 4.87 | MA | Strong Buy |
TTM vs. 5-year historical average (annual ratios)
| Metric | AGEN | Historical (5Y) / ref | Status |
|---|---|---|---|
| P/E ratio (TTM) | 2.3x | -191.7x · sector 20.7x | Discount |
| Forward P/E (FY26E) | 23.7x | EPS est. 0.27 | Elevated |
| Price / Book | -1.3x | 1.6x | Discount |
| Price / Sales | 2.2x | 2.5x | Discount |
| EV / EBITDA | 2.0x | 2.3x | In line |
| Return on equity | -38.1% | — | Weak |
| Gross margin | 99.5% | -27.2% | Below hist. |
| Debt / Equity | -0.20 | -0.34 | Conservative |
| Piotroski / Altman Z | 6/9 | Z -14.34 | Distress |
Discounted cash flow model
Free float vs. closely held shares
13F institutional holdings are not available in the current data plan.
SEC Form 4 filings
| Date | Insider | Role | Type | Shares @ price | Value |
|---|---|---|---|---|---|
| Oct 1, 26 | Wright Timothy | director | A-Award | 1,179 | — |
| Oct 1, 26 | Harrison Thomas L | director | A-Award | 4,443 @ $6.89 | $30.63K |
| Aug 5, 26 | Marcucci Marco Tullio | director | A-Award | 7,500 @ $7.78 | $58.35K |
| Aug 5, 26 | Marcucci Marco Tullio | director | 0 | — | |
| Aug 5, 26 | Marcucci Marco Tullio | director | 0 | — | |
| Aug 10, 26 | Armen Garo H | director, officer: See Remarks | A-Award | 1,971,500 @ $7.78 | $15.34M |
| Aug 5, 26 | Harrison Thomas L | director | A-Award | 50,000 @ $7.78 | $389.0K |
| Aug 5, 26 | Corvese Brian | director | A-Award | 100,000 @ $7.78 | $778.0K |
FY2025 · 10-K disclosure
FY2025 · 10-K disclosure
Stock news · updated daily
LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #AGEN--Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that the Company will release its third quarter 2026 financial results before the market opens on Thursday, November 5, 2026. The earnings release will review Agenus' recent progress in advancing botensilimab and balstilimab (BOT+BAL) toward the Phase 3 neoadjuvant ROBBIN trial in earlier-stage colon cancer and strengthening the clinical and regulatory foundation for.
Agenus NASDAQ: AGEN is concentrating its registration strategy for BOT/BAL on the Phase III ROBBIN trial in neoadjuvant high-risk stage II and III microsatellite-stable (MSS) colon cancer, after ending funding for its BATTMAN study in later-line metastatic disease.
Agenus Inc. (NASDAQ: AGEN - Get Free Report) has earned an average recommendation of "Moderate Buy" from the six research firms that are currently covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, one has given a hold recommendation and four have assigned a buy recommendation to the company.
LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #Botensilimab--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that Zack Armen, Head of Corporate Development and Investor Relations, will participate in a fireside chat and one-on-one investor meetings at Chardan's 10th Annual Healthcare Conference: The Next 10 Years of Disruptive Innovation, on October 20, 2026. Chardan 10th Annual Healthcare Conference: The Next 10 Years of Disruptive Innovation Date: Tuesday, October 20, 2026 Location:.
LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #Armenia--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that the Ministry of Health of the Republic of Armenia has granted marketing authorizations for Botvymo® (botensilimab, BOT) and Evamplix® (balstilimab, BAL), each approved for use in combination with the other for the treatment of adult patients with microsatellite stable (MSS) metastatic colorectal cancer (mCRC) without active liver metastases who have previously received ava.
ImageneBio (NASDAQ: IMA - Get Free Report) and Agenus (NASDAQ: AGEN - Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, institutional ownership, risk, dividends, earnings, profitability and analyst recommendations. Insider and Institutional Ownership 75.0% of ImageneBio shares are
Agenus (NASDAQ: AGEN - Get Free Report)'s stock had its "buy" rating reiterated by equities research analysts at Chardan Capital in a research report issued on Monday, Benzinga reports. They currently have a $40.00 price objective on the biotechnology company's stock. Chardan Capital's target price indicates a potential upside of 378.47% from the stock's previous close.
[url="]Agenus[/url] Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced three-year follow-up results from the ovarian cancer cohort of
Reported EPS vs. consensus estimate
| Report date | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|
| Aug 6, 2026 | 0.05 | -0.01 | Miss -122.2% | $34.50M |
| May 11, 2026 | 2.10 | 1.02 | Miss -51.4% | $33.70M |
| Mar 16, 2026 | -1.27 | 0.56 | Beat 144.1% | $34.20M |
| Nov 10, 2025 | 2.63 | 1.94 | Miss -26.2% | $30.23M |
| Aug 11, 2025 | -0.78 | -1.00 | Miss -28.2% | $25.69M |
| May 12, 2025 | -1.61 | -1.03 | Beat 36.0% | $24.07M |
| S-3 | Sep 11, 2026 | 2026-09-11 16:46:15 | View |
| S-8 | Sep 2, 2026 | 2026-09-02 16:30:53 | View |
| 8-K | Aug 18, 2026 | 2026-08-18 16:30:14 | View |
| 424B3 | Aug 17, 2026 | 2026-08-17 06:01:52 | View |
| EFFECT | Aug 14, 2026 | 2026-08-17 00:15:19 | View |
| 8-K | Aug 13, 2026 | 2026-08-12 21:30:17 | View |
Proxy statement (DEF 14A) disclosures